This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Editas Medicine, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Innovations of Fred Harbinski in CRISPR-Cas9 Technology
Introduction
Fred Harbinski is an accomplished inventor based in Cambridge, MA (US). He has made significant contributions to the field of genetic editing, particularly through his work with CRISPR-Cas9 technology. His innovative approach has the potential to revolutionize immunotherapy.
Latest Patents
Fred Harbinski holds a patent titled "Methods, Compositions and Components for CRISPR-Cas9 Editing of TGFBR2 in T Cells for Immunotherapy." This patent represents a critical advancement in the application of CRISPR technology for therapeutic purposes, specifically targeting TGFBR2 in T cells.
Career Highlights
Harbinski is currently associated with Editas Medicine, Inc., a leading company in the field of gene editing. His work at Editas has positioned him at the forefront of innovative research and development in genetic therapies.
Collaborations
Fred has collaborated with notable colleagues, including Stephen Michael Burleigh and Melissa Chin. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in the field of immunotherapy.
Conclusion
Fred Harbinski's contributions to CRISPR-Cas9 technology exemplify the innovative spirit of modern science. His work not only advances the field of genetic editing but also holds promise for future therapeutic applications.